Recipharm Appoints New Position of Vice President Quality Management
Recipharm has appointed Thomas Beck to the new senior role of Vice President Quality Management (VP QM) with effect from 1st April 2015. Thomas is currently Head of Quality Control and Assurance at Recipharm Stockholm, a position that he has held since 2010. He is also Chairman of the Quality Assurance section within the Swedish Academy of Pharmaceutical Science.
In this new role Thomas will drive and co-ordinate the quality strategy and policy across the Recipharm Group subsidiaries and assist the Group Management Team (GMT) in monitoring and evaluating the company’s quality efforts. He will also lead the company’s audit process and support the sales activity by providing a primary contact point for new customers’ regulatory and quality affairs departments.
Reporting to the EVP Chief Operation Officer, this post represents an expansion of the Group Management Team in a move designed to help it meet the increased demands the group is facing following the recent rapid growth.
Commenting on the new appointment, Thomas Eldered, CEO of Recipharm, remarked: “This new position will bolster and enhance the work of the Group Management Team, meeting head on the quality management challenges our industry faces. Thomas will take a pivotal role in ensuring that we deliver and practice the highest standards of quality right across the entire Recipharm Group. He personally brings strong quality management expertise and already has specific experience of operations at Recipharm and the high standards that we are committed to delivering for our customers. I very much look forward to his authoritative support and direction being brought to bear for the benefit of the Group as a whole.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.